Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr:125:102719.
doi: 10.1016/j.ctrv.2024.102719. Epub 2024 Mar 12.

Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection

Elena Brozos-Vázquez  1 , Marta Toledano-Fonseca  2 , Nicolás Costa-Fraga  3 , María Victoria García-Ortiz  2 , Ángel Díaz-Lagares  4 , Antonio Rodríguez-Ariza  5 , Enrique Aranda  6 , Rafael López-López  7
Affiliations
Free article
Review

Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection

Elena Brozos-Vázquez et al. Cancer Treat Rev. 2024 Apr.
Free article

Abstract

Pancreatic cancer is one of the tumors with the worst prognosis, and unlike other cancers, few advances have been made in recent years. The only curative option is surgery, but only 15-20% of patients are candidates, with a high risk of relapse. In advanced pancreatic cancer there are few first-line treatment options and no validated biomarkers for better treatment selection. The development of targeted therapies in pancreatic cancer is increasingly feasible due to tumor-agnostic treatments, such as PARP inhibitors in patients with BRCA1, BRCA2 or PALB2 alterations or immunotherapies in patients with high microsatellite instability/tumor mutational burden. In addition, other therapeutic molecules have been developed for patients with KRAS G12C mutation or fusions in NTRK or NRG1. Consequently, there has been a growing interest in biomarkers that may help guide targeted therapy in pancreatic cancer. Therefore, this review aims to offer an updated perspective on biomarkers with therapeutic potential in pancreatic cancer.

Keywords: Agnostic therapy; MSI-H; Pancreatic adenocarcinoma; Potential therapeutic biomarkers; TMB.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: EB-V has received travel, accommodations, expenses from Lilly, Merck, Amgen, Roche, Servier, LEO Pharma, Rovi, Sanofi, Pfizer, Daiichi-Sankyo; honoraria for educational activities from LEO Pharma, Rovi, Roche, Kiowa Kirin, Merck, Bayer, Pierre Fabre, Sanofi, Amgen; honoraria for consultancies from Servier, Pfizer, Bayer. EA has received honoraria for advisory role from Amgen, Bayer, Sanofi, Incyte and Pierre Fabre. The rest of authors declare no competing interests. RL-L has received honoraria for participation in Advisory Boards from Roche, AstraZeneca, Merck, MSD, Bayer, BMS, Novartis, Janssen, Lilly, Pfizer and Leo; travel, accommodations and expenses from Pharmamar, Roche, BMS and Pierre Fabre; research funding from Roche and Merck; and is co-founder and shareholder in Nasasbiotech, Diversa Technologies.

Substances